Literature DB >> 21743483

Abiraterone acetate for prostate cancer: a new era of hormonal therapies.

Emmanuel S Antonarakis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21743483      PMCID： PMC3739597          DOI： 10.1038/aja.2011.92

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  12 in total

Review 1.  Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.

Authors:  E S Antonarakis; A J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-05-17       Impact factor: 5.554

2.  Expanding treatment options for metastatic prostate cancer.

Authors:  Emmanuel S Antonarakis; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

3.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

4.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

Review 5.  New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.

Authors:  Gerhardt Attard; Juliet Richards; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

6.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

7.  Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Authors:  Charles J Ryan; Matthew R Smith; Lawrence Fong; Jonathan E Rosenberg; Philip Kantoff; Florence Raynaud; Vanessa Martins; Gloria Lee; Thian Kheoh; Jennifer Kim; Arturo Molina; Eric J Small
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

8.  Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.

Authors:  Mari Nakabayashi; William K Oh; Susanna Jacobus; Meredith M Regan; Mary-Ellen Taplin; Philip W Kantoff; Jonathan E Rosenberg
Journal:  BJU Int       Date:  2009-10-23       Impact factor: 5.588

9.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Authors:  Eric J Small; Susan Halabi; Nancy A Dawson; Walter M Stadler; Brian I Rini; Joel Picus; Preston Gable; Frank M Torti; Ellen Kaplan; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

10.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544
View more
  1 in total

1.  Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.

Authors:  Jingsong Zhang; Jessica J Cunningham; Joel S Brown; Robert A Gatenby
Journal:  Nat Commun       Date:  2017-11-28       Impact factor: 14.919
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.